AUTOIMMUNE DISEASES | Continued
References 1.
“Autoimmune Disease List.” American Autoimmune Related Diseases Association, Inc., 2018, https://www.aarda.org/ diseaselist/.
2.
“Medicines in Development for Autoimmune Diseases 2016 Report.” PhRMA, Sept. 12, 2016, https://www.phrma.org/en/ Report/Medicines-in-Development-for-Autoimmune-Diseases2016-Report.
3.
McCain, Jack. “The Disease Burden of the Most Common Autoimmune Diseases.” Managed Care, July 19, 2016, https:// www.managedcaremag.com/archives/2016/7/disease-burdenmost-common-autoimmune-diseases.
4.
“Autoimmune Disease.” U.S. Pharmacist, June 16, 2016, https:// www.uspharmacist.com/article/autoimmune-disease.
5.
Wyant, Tim et al. “An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.” Journal of Crohn’s and Colitis, Dec. 2016, https://www.ncbi.nlm.nih.gov/pubmed/27252400.
6.
“Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value Evidence Report.” Institute for Clinical and Economic Review, April 7, 2017, https://icer-review.org/ wp-content/uploads/2016/08/NE_CEPAC_RA_Evidence_Report_ FINAL_040717.pdf.
7.
Humira® [package insert]. North Chicago, IL: AbbVie; 2019.
8.
Cimzia® [package insert]. Smyrna, GA: UCB; 2019.
9.
Enbrel® [package insert]. Thousand Oaks, CA: Amgen; 2018.
10. Simponi® [package insert]. Horsham, PA: Janssen Pharmaceutica; 2019. 11. Remicade® [package insert]. Horsham, PA: Janssen Pharmaceutica; 2018. 12. Rituxan® [package insert]. South San Francisco, CA: Genentech; 2019. 13. Siliq™ [package insert]. Bridgewater, NJ: Bausch Health; 2017. 14. Taltz® [package insert]. Indianapolis, IN: Eli Lilly; 2019. 15. Tremfya® [package insert]. Horsham, PA: Janssen Pharmaceutica; 2019. 16. Skyrizi™ [package insert]. North Chicago, IL: AbbVie; 2019. 17. Kevzara® [package insert]. Bridgewater, NJ: Sanofi/Regeneron; 2018. 18. Actemra® [package insert]. South San Francisco, CA: Genentech, Inc; 2019. 19. Ilumya™ [package insert]. Whitehouse Station, NJ: Merck & Co; 2018. 20. Cosentyx® [package insert]. East Hanover, NJ: Novartis; 2018. 21. Stelara® [package insert]. Horsham, PA: Janssen Pharmaceutica; 2019. 22. Entyvio® [package insert]. Deerfield, IL: Takeda; 2019. 23. Olumiant® [package insert]. Indianapolis, IN: Eli Lilly; 2019. 24. Xeljanz® [package insert]. New York, NY: Pfizer; 2019.
12 | Magellan Rx Report | Spring 2020
25. Rinvoq™ [package insert]. North Chicago, IL: AbbVie; 2019. 26. Orencia® [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2019. 27. “Biosimilar Product Information.” U.S. Food and Drug Administration, Nov. 15, 2019, https://www.fda.gov/drugs/biosimilars/biosimilarproduct-information. 28. “Pfizer announces the U.S. availability of biosimilar Inflectra® (infliximab-dyyb).” Oct. 17, 2016, https://www.pfizer.com/news/ press-release/press-release-detail/pfizer_announces_the_u_s_ availability_of_biosimilar_inflectra_infliximab_dyyb. 29. “Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case.” GlobeNewswire, Aug. 9, 2019, https://www.globenewswire.com/newsrelease/2019/08/09/1900111/0/en/Sandoz-will-appeal-DistrictCourt-of-New-Jersey-ruling-in-biosimilar-Erelzi-etanercept-szzs-USpatent-case.html. 30. “Product Profile: Adalimumab-atto (Amjevita).” BR&R Biosimilars Review & Report, 2019, https://biosimilarsrr.com/product-profileamjevita-2-2-2/. 31. Gifford, C. Nichole. “Samsung Bioepis and Merck Launch Renflexis® in the US.” Rothwell Figg, 2018, https://www.biosimilarsip. com/2017/08/09/samsung-bioepis-merck-launch-renflexis-u-s/. 32. “Boehringer Ingelheim announces resolution of Cyltezo® patent litigation.” Boehringer Ingelheim, May 14, 2019, https://www. boehringer-ingelheim.us/press-release/boehringer-ingelheimannounces-resolution-cyltezo-patent-litigation. 33. Stanton, Dan. “Pfizer: ‘No plans to launch second approved Remicade biosimilar in US’.” BioPharma Reporter, Dec. 14, 2017, updated Nov. 16, 2018, https://www.biopharma-reporter.com/Article/2017/12/14/ Pfizer-No-plans-to-launch-second-infliximab-biosimilar-in-US. 34. “FDA Approves Sandoz’s Biosimilar Adalimumab, Hyrimoz.” The Center for Biosimilars, Oct. 31, 2018, https://www. centerforbiosimilars.com/news/fda-approves-sandozs-biosimilaradalimumab-hyrimoz. 35. Davio, Kelly. “First Rituximab Biosimilar, Truxima, Launches in the United States.” The Center for Biosimilars, Nov. 7, 2019, https://www. centerforbiosimilars.com/news/first-rituximab-biosimilar-truximalaunches-in-the-united-states. 36. Holt, Benjamin R. “Another Biosimilar Receives FDA Approval and Is Confronted with Litigation.” Rothwell Figg, 2019, https://www. biosimilarsip.com/2019/05/28/another-biosimilar-receives-fdaapproval-and-is-confronted-with-litigation/. 37. Davio, Kelly. “Pfizer Announces Launch Dates for 2 More Anticancer Biosimilars: Ruxience and Trazimera.” The Center for Biosimilars, Oct. 29, 2019, https://www.centerforbiosimilars.com/news/ pfizer-announces-launch-dates-for-2-more-anticancer-biosimilarsruxience-and-trazimera. 38. “FDA Approves Samsung Bioepis’ HADLIMA™ (adalimumab-bwwd).” BioSpace, July 24, 2019, https://www.biospace.com/article/releases/ fda-approves-samsung-bioepis-hadlima-adalimumab-bwwd-/.
